Chapter 2. Antimicrobial Resistance

Retail Meat Surveillance

Key Findings

Beef

Escherichia Coli (n = 362)

As in previous years, resistance levels (= 1%) of category I β-lactam amoxicillin-clavulanic acid, ceftriaxone, and ceftiofur remained low in beef E. coli isolates in 2012 (Table 9). No ciprofloxacin resistance was observed in 2012 (Table 9). One isolate (1%, 1/107) from Ontario was resistant to azithromycin (Table 9).

Chicken

Salmonella (n = 307)

Across all provinces^{Footnote 8} sampled, the top 3 chicken Salmonella serovars were S. Heidelberg, S. Kentucky, and S. Enteritidis. Regional differences in serovar distribution were observed in 2012 with S. Enteritidis being the most common serovar in both British Columbia (34%, 18/53) and Saskatchewan (30%, 14/46) unlike Ontario and Québec where the most common serovar was S. Heidelberg (41%, 42/102 and 40%, 40/106 respectively) (Table 10). No S. Enteritidis was recovered in Québec.

All S. Enteritidis isolates were susceptible to all antimicrobials tested in 2012. No ciprofloxacin resistance was observed in any serotype in 2012 (Table 10). Nalidixic acid resistance was observed in 2 S. Kentucky isolates (4%, 2/53) from British Columbia (Table 10); previously nalidixic acid resistance has only been observed in 2 isolates (S. Hadar and S. 4,[5],12:i-) from Saskatchewan in 2005.

Category I β-lactam (amoxicillin-clavulanic acid, ceftriaxone, ceftiofur) resistance levels (26%, 80/307) remained similar to levels in 2011 (30%, 108/361). Resistance to ceftiofur (23%, 23/102) was significantly lower in 2012 than 2004 (46%, 25/54) in Ontario (Figure 11). Although resistance to ceftiofur (28%, 30/106) was significantly lower in 2012 than 2003 (50%, 14/28) in Québec, ceftiofur resistance in Québec was significantly higher in 2012 compared to 2006 (9%, 3/33) (Figure 11).

Escherichia Coli (n = 373)

No ciprofloxacin resistance was observed in chicken E. coli isolates in 2012 (Table 11). Resistance levels of category I β-lactam amoxicillin-clavulanic acid, ceftriaxone, and ceftiofur remain similar to those in 2011. Resistance to ceftiofur was significantly higher in 2012 (22%, 14/64) than 2005 (4%, 3/82) in Saskatchewan (Figure 12). Resistance to ceftiofur was significantly higher in 2012 (25%, 32/128) than 2006 (6%, 8/135) in Québec (Figure 12). One isolate (1%, 1/128) from Québec was resistant to azithromycin (Table 11).

Campylobacter (n = 280)

Low-level (3%, 3/88) of telithromycin resistance was observed in Campylobacter isolates from Ontario in 2012 (Table 12); this is similar to levels in recent previous years.

In 2012, ciprofloxacin resistance continues to decline in British Columbia (8%, 6/73) and remains at a similar level in Saskatchewan (5%, 2/40) compared to 2011 (4%, 1/25) (Figure 13). In isolates from Ontario, ciprofloxacin resistance has significantly increased in 2012 (16%, 14/88) compared to 2011 (6%, 4/71) and 2003 (4%, 3/78) (Figure 13). Resistance to azithromycin was significantly lower in 2012 (8%, 6/79) than 2003 (22%, 21/94) in Québec (Figure 13).

Pork

Escherichia Coli (n = 193)

Recovery of E. coli from retail pork continues to decline overall and remains relatively low (Table 25).

No key findings were found with respect to antimicrobial resistance.

Turkey

In 2012, no statistical temporal analyses were performed for retail ground turkey samples. Additionally, no temporal variation figures were presented as 2012 was the first year for retail ground turkey sampling.

Salmonella (n = 140)

The distribution of Salmonella serovars varies by province in the first full year of retail surveillance of ground turkey (Table 14).

No ciprofloxacin or nalidixic acid resistance was observed (Table 14). One (2%, 1/44) S. Indiana isolate from Ontario was resistant to 6 antimicrobial classes (Table 14) and presented the ACKSSuT-A2C-AZM-CRO-GEN-SXT resistance pattern.

Escherichia Coli (n = 504)

One (1%, 1/152) retail turkey isolate of E. coli from Ontario was resistant to 7 classes of antimicrobials tested (Table 15) and had the following resistance pattern: ACKSSuT-A2C-AZM-CRO-CIP-GEN-NAL-SXT.

Campylobacter (n = 74)

Two isolates (10%, 2/20) from Ontario were resistant to telithromycin in 2012 (Table 16). Ciprofloxacin resistance was observed in 21% (7/33) of isolates from British Columbia and 1 (1/6) isolate from Saskatchewan (Table 16).

Multiclass Resistance

**Table 9. Number of antimicrobial classes in resistance patterns of *Escherichia* coli from beef**
Province or region	Number (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides			β-lactams					Folate pathway inhibitors		Macrolides	Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	KAN	STR	AMP	AMC	CRO	FOX	TIO	SSS	SXT	AZM	CHL	CIP	NAL	TET
British Columbia	70 (19.3)	46	7	15	2			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	1	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1	15	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		2			24
Saskatchewan	78 (21.5)	62	6	10					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	1	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1	8						14
Ontario	110 (30.4)	73	13	18	5	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		18	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	3		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	33
Québec	104 (28.7)	86	7	10	1			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3					8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2		1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	16

**Table 10. Number of antimicrobial classes in resistance patterns of *Salmonella* from chicken**
Province or region / serovar	Numbers (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides			β-lactams					Folate pathway inhibitors		Macrolides	Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	KAN	STR	AMP	AMC	CRO	FOX	TIO	SSS	SXT	AZM	CHL	CIP	NAL	TET
British Columbia
Enteritidis	18 (34)	18
Kentucky	15 (28.3)		1	12	2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13	13	13	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11	13						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	14
Heidelberg	7 (13.2)	1	6							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	6	6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	6
Hadar	5 (9.4)	4		1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1												1
Infantis	2 (3.8)	2
Mbandaka	2 (3.8)	1	1																		1
Less common serovars	4 (7.5)	2	2							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	2	2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	2
Total	53 (100)	28	10	13	2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21	21	21	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19	21						2	16
Saskatchewan
Enteritidis	14 (30.4)	14
Kentucky	10 (21.7)	2	3	5					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	5	5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	5							5
Heidelberg	5 (10.9)	5
Infantis	4 (8.7)	3	1							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1
Thompson	4 (8.7)	4
Hadar	2 (4.3)	1		1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1												1
Schwarzengrund	2 (4.3)	2
Typhimurium	2 (4.3)				2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2					2			2			2
Livingstone var.14+	1 (2.2)	1
Mbandaka	1 (2.2)		1																		1
Senftenberg	1 (2.2)	1
Total	46 (100)	33	5	6	2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8	6	6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	6	2			2			9
Ontario
Heidelberg	42 (41.2)	26	16							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15	12	12	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12	12							1
Kentucky	34 (33.3)	11	3	20					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	9	9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	9							21
Enteritidis	3 (2.9)	3
Kiambu	3 (2.9)			3						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3											3
Less common serovars	20 (19.6)	12	3	3	2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	2	2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	2	3			1			5
Total	102 (100)	52	22	26	2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32	23	23	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21	23	3			1			30
Québec
Heidelberg	40 (37.7)	27	13							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13	12	12	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11	12
Kentucky	32 (30.2)	5		27					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11	11	11	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11	11							27
Thompson	13 (12.3)	12	1							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1
I 4,[5],12:r:-	3 (2.8)		3							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	3	3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	3
Less common serovars	18 (17)	9	2	6	1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	3	3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	3	6			1			6
Total	106 (100)	53	19	33	1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31	30	30	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29	30	6			1			33

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

**Table 11. Number of antimicrobial classes in resistance patterns of *Escherichia coli* from chicken**
Province or region	Number (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides			β-lactams					Folate pathway inhibitors		Macrolides	Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	KAN	STR	AMP	AMC	CRO	FOX	TIO	SSS	SXT	AZM	CHL	CIP	NAL	TET
British Columbia	74 (19.8)	19	15	23	17		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44	32	30	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30	29	26	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7		8		3	31
Saskatchewan	64 (17.2)	23	17	18	6		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18	15	14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15	14	13	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1				5	23
Ontario	107 (28.7)	32	19	47	9		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47	21	20	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21	20	29	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8		1		2	52
Québec	128 (34.3)	29	19	52	28		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56	34	34	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34	32	63	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	5		2	76

**Table 12. Number of antimicrobial classes in resistance patterns of *Campylobacter* from chicken**
Province or region / species	Numbers (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides	Ketolides	Lincosamides	Macrolides		Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	TEL	CLI	AZM	ERY	FLR	CIP	NAL	TET
British Columbia
Campylobacter jejuni	66 (90.4)	48	16	2									3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	17
Campylobacter coli	7 (9.6)	3	3	1									3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	2
Total	73 (100)	51	19	3									6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	19
Saskatchewan
Campylobacter jejuni	36 (90)	17	16	3						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	19
Campylobacter coli	3 (7.5)	2	1												1
Campylobacter spp.	1 (2.5)	1
Total	40 (100)	20	17	3						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	20
Ontario
Campylobacter jejuni	75 (85.2)	34	29	12				2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4		10	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10	38
Campylobacter coli	10 (11.4)	5	2	2	1			1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2		1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	4
Campylobacter spp.	3 (3.4)		3										3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3
Total	88 (100)	39	34	14	1			3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6		14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14	42
Québec
Campylobacter jejuni	76 (96.2)	25	45	6					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6		1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	49
Campylobacter coli	3 (3.8)	2		1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1				1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1
Total	79 (100)	27	45	7					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6		2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	50
Maritimes
Campylobacter jejuni	8 (88.9)	5	3												3
Campylobacter coli	1 (11.1)		1												1
Total	9 (100)	5	4												4

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.

**Table 13. Number of antimicrobial classes in resistance patterns of *Escherichia coli* from pork**
Province or region	Number (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides			β-lactams					Folate pathway inhibitors		Macrolides	Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	KAN	STR	AMP	AMC	CRO	FOX	TIO	SSS	SXT	AZM	CHL	CIP	NAL	TET
British Columbia	37 (19.2)	26	4	5	2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	4	4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	4	4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	9
Saskatchewan	26 (13.5)	16	2	7	1				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	1	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	1	5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2		2			9
Ontario	86 (44.6)	33	13	32	8			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25	2	2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	1	20	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4		7			50
Québec	44 (22.8)	21	4	13	6		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8	1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		17	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4		3		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	21

**Table 14. Number of antimicrobial classes in resistance patterns of *Salmonella* from turkey**
Province or region / serovar	Numbers (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides			β-lactams					Folate pathway inhibitors		Macrolides	Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	KAN	STR	AMP	AMC	CRO	FOX	TIO	SSS	SXT	AZM	CHL	CIP	NAL	TET
British Columbia
Enteritidis	7 (25.9)	7
Kentucky	7 (25.9)			7					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6							7
Hadar	5 (18.5)			5					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5												5
Heidelberg	3 (11.1)	1	2							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2
Agona	2 (7.4)			1	1				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	2						2
Johannesburg	1 (3.7)	1
Newport	1 (3.7)	1
Schwarzengrund	1 (3.7)	1
Total	27 (100)	11	2	13	1				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9	2						14
Saskatchewan
Derby	3 (16.7)			3					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3						3						3
Agona	2 (11.1)			1	1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	2						2
Hadar	2 (11.1)			2			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2						2						2
Heidelberg	2 (11.1)	1	1																		1
Meleagridis	2 (11.1)	2
Alachua	1 (5.6)	1
Kentucky	1 (5.6)			1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1												1
Mbandaka var.14+	1 (5.6)		1																		1
Reading	1 (5.6)	1
Schwarzengrund	1 (5.6)			1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1						1						1
Typhimurium var. 5-	1 (5.6)				1				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1					1			1			1
Uganda	1 (5.6)	1
Total	18 (100)	6	2	8	2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	9			1			12
Ontario
Heidelberg	14 (31.8)	11	2	1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3
Enteritidis	5 (11.4)	5
Saintpaul	5 (11.4)	5
Infantis	3 (6.8)	1	1		1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	1			1			1
Schwarzengrund	3 (6.8)	3
Hadar	2 (4.5)			2					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2												2
Indiana	2 (4.5)				1	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	2			2
Typhimurium	2 (4.5)	1			1			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1					1			1			1
Worthington	2 (4.5)	1	1							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1
Albany	1 (2.3)			1			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1
I 4,[5],12:i:-	1 (2.3)	1
I 6,7:-:1,5	1 (2.3)	1
Johannesburg	1 (2.3)	1
Kentucky	1 (2.3)			1					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1												1
Typhimurium var. 5-	1 (2.3)				1				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1					1			1			1
Total	44 (100)	30	4	5	4	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	11	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9	5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	5			8
Québec
Heidelberg	9 (17.6)		4	3	2				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6	2						6
Saintpaul	9 (17.6)	9
Agona	6 (11.8)	1	5							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5
Muenster	5 (9.8)	3		2					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2
Schwarzengrund	5 (9.8)	2		3			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3						3						2
Worthington	3 (5.9)	2	1							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1
Kentucky	2 (3.9)			2					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1							2
Kiambu	2 (3.9)			2					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2					2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2
Liverpool	2 (3.9)	2
Thompson	2 (3.9)	2
Less common serovars	6 (11.8)	2	1	3					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	1						2
Total	51 (100)	23	11	15	2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15	8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2					12

**Table 15. Number of antimicrobial classes in resistance patterns of *Escherichia coli* from turkey**
Province or region	Number (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides			β-lactams					Folate pathway inhibitors		Macrolides	Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	KAN	STR	AMP	AMC	CRO	FOX	TIO	SSS	SXT	AZM	CHL	CIP	NAL	TET
British Columbia	101 (20.0)	35	17	41	8		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31	16	14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15	13	26	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3		2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	47
Saskatchewan	81 (16.1)	30	12	31	8		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20	4	3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	3	20	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1		1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	42
Ontario	152 (30.2)	49	34	49	19	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47	17	14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16	13	42	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	8	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	90
Québec	170 (33.7)	55	27	67	21		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64	21	19	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20	19	49	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20		10			99

**Table 16. Number of antimicrobial classes in resistance patterns of *Campylobacter* from turkey**
Province or region / species	Numbers (%) of isolates	Number of isolates by number of antimicrobial classes in the resistance pattern					Number of isolates resistant by antimicrobial class and antimicrobial
							Aminoglycosides	Ketolides	Lincosamides	Macrolides		Phenicols	Quinolones		Tetracyclines
		0	1	2-3	4-5	6-7	GEN	TEL	CLI	AZM	ERY	FLR	CIP	NAL	TET
British Columbia
Campylobacter jejuni	26 (78.8)	20	3	3									Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3	6
Campylobacter coli	7 (21.2)		4	3									Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4	6
Total	33 (100)	20	7	6									Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7	12
Saskatchewan
Campylobacter jejuni	6 (100)	2	3	1									Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	4
Total	6 (100)	2	3	1									Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	4
Ontario
Campylobacter jejuni	12 (60)	1	10	1				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1				10
Campylobacter coli	8 (40)	2	5	1				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1				5
Total	20 (100)	3	15	2				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2	1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2				15
Québec
Campylobacter jejuni	14 (93.3)	3	11												11
Campylobacter coli	1 (6.7)	1
Total	15 (100)	4	11												11

Temporal Antimicrobial Resistance Summary

Figure 10. Temporal variations in resistance of Escherichia coli isolates from beef

**Figure 10. Temporal variations in resistance of *Escherichia coli* isolates from beef**
Antimicrobial
Province	British Columbia							Saskatchewan									Ontario											Québec											Maritimes
Year	'07	'08	'09	'10	'11	'12		'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'08	'09	'10	'11
Number of isolates	49	88	79	64	57	70		120	123	118	134	135	107	54	78		101	191	184	189	187	185	195	123	161	110		84	137	126	109	147	126	108	101	91	104		39	135	126	110
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013. The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.
Ampicillin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	6%	3%	6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%			Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	1%	3%	1%	0%	4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%	5%	3%	4%	3%	6%	3%	4%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%	4%	6%	4%	3%	2%	6%		3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%		3%	6%	2%	1%
Ceftiofur	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	2%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	0%	1%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	1%		0%	1%	0%	1%	1%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	2%	1%		0%	1%	1%	1%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	3%	1%	1%	0%
Gentamicin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	1%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%		0%	0%	0%	1%	1%	2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	0%	1%		0%	0%	0%	0%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	0%
Nalidixic acid	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	0%	0%	2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	1%		0%	1%	1%	0%	0%	3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	1%	0%		0%	0%	0%	1%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	0%	0%	0%	1%
Streptomycin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	9%	4%	8%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%		2%	1%	5%	3%	6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11%	6%		5%	4%	3%	11%	13%	11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%	9%	4%		6%	7%	7%	9%	8%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%	5%	7%	2%	3%
Tetracycline	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10%	23%	10%	16%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%		9%	8%	20%	13%	14%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.23%	19%		17%	15%	14%	21%	23%	18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%	15%	17%		20%	15%	17%	12%	15%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15%	18%	19%	12%	11%
Trimethoprim-sulfamethoxazole	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	0%	4%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%		0%	0%	1%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	2%		1%	2%	2%	3%	4%	6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	2%	3%		2%	2%	1%	2%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	3%	2%	2%	1%

Figure 11. Temporal variations in resistance of Salmonella isolates from chicken

**Figure 11. Temporal variations in resistance of *Salmonella* isolates from chicken**
Antimicrobial
Province	British Columbia							Saskatchewan									Ontario											Québec											Maritimes
Year	'07	'08	'09	'10	'11	'12		'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'08	'09	'10	'11
Number of isolates	18	47	59	56	64	53		21	25	43	64	71	42	29	46		26	54	26	36	172	139	142	90	119	102		28	53	26	33	113	120	105	116	100	106		12	96	77	49
For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (bold numbers). The presence of underlined areas indicates significant differences (P ≤ 0.05) for a given province/region and antimicrobial. Additional temporal analyses for ampicillin and ceftiofur were conducted for Salmonella isolates from Ontario and Québec. These two antimicrobials, provinces, and years (2004 and 2006) were selected due to a change in ceftiofur use practices by Québec chicken hatcheries in early 2005 and in 2007 (start and end of the voluntary period of withdrawal). Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results are indicated by underlined numbers. Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013. The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.
Ampicillin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39%	28%	27%	25%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.40%			Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	12%	23%	9%	24%	19%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%	52%	19%	17%	16%	14%	32%	29%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.33%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31%		Significant differences (P ≤ 0.05) for a given antimicrobial.61%	49%	23%	15%	16%	21%	39%		34%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30%	Significant differences (P ≤ 0.05) for a given antimicrobial.29%		17%	29%	23%	29%
Ceftiofur	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.33%	23%	27%	25%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.40%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		4%	2%	5%	15%	7%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12%	Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.46%		15%	14%	11%	10%	24%	24%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.23%	Significant differences (P ≤ 0.05) for a given antimicrobial.50%	40%	15%		Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.9%	9%	15%	20%	25%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%	Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.28%	17%	23%	21%	29%
Gentamicin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	0%		0%	0%	2%	1%	1%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	2%	0%		0%	3%	2%	1%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	8%	1%	0%	0%
Nalidixic acid	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10%		0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%		0%	0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%		0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	0%
Streptomycin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11%	30%	14%	27%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43%		20%	37%	36%	23%	24%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	4%		12%	25%	31%	32%	35%	29%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21%	23%	8%		39%	37%	31%	30%	25%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30%	17%	27%	25%	41%
Tetracycline	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%	30%	15%	29%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.22%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.52%		32%	35%	36%	27%	17%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	4%		8%	25%	34%	36%	35%	33%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21%	23%	8%		39%	37%	35%	30%	24%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.53%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31%	8%	29%	26%	43%
Trimethoprim-sulfamethoxazole	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	2%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	2%		0%	3%	1%	1%	1%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%		0%	0%	0%	3%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	3%	0%

Figure 12. Temporal variations in resistance of Escherichia coli isolates from chicken

**Figure 12. Temporal variations in resistance of *Escherichia coli* isolates from chicken**
Antimicrobial
Province	British Columbia							Saskatchewan									Ontario											Québec											Maritimes
Year	'07	'08	'09	'10	'11	'12		'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'08	'09	'10	'11
Number of isolates	42	70	70	75	70	74		82	85	75	92	90	71	38	64		136	150	145	152	157	150	155	100	137	107		111	158	142	135	128	131	126	138	133	128		37	185	175	171
For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given province/region and antimicrobial. Additional temporal analyses for ampicillin and ceftiofur were conducted for E. coli isolates from Ontario and Québec. These two antimicrobials, provinces, and years (2004 and 2006) were selected due to a change in ceftiofur use practices by Québec chicken hatcheries in early 2005 and in 2007 (start and end of the voluntary period of withdrawal). Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results are indicated by underlined numbers. Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013. The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.
Ampicillin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.60%	63%	61%	63%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.66%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.59%			Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%	31%	35%	40%	36%	35%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35%	39%	33%	42%	39%	39%	41%	39%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50%	52%	49%	35%	34%	33%	41%		54%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44%		30%	42%	40%	52%
Ceftiofur	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%	49%	41%	44%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39%	Significant differences (P ≤ 0.05) for a given antimicrobial.4%		6%	13%	20%	22%	20%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%	Significant differences (P ≤ 0.05) for a given antimicrobial.22%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18%	21%		17%	22%	22%	24%	21%	21%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.32%	34%	25%		Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.6%	13%	18%	19%	27%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.25%	19%	27%	18%	33%
Gentamicin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	6%	1%	3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%		6%	11%	9%	8%	6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%	5%		7%	6%	13%	12%	7%	18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%	10%	11%		21%	24%	21%	27%	18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%	5%	15%	14%	18%
Nalidixic acid	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	4%	7%	7%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%		4%	5%	7%	4%	10%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	1%		1%	3%	3%	4%	3%	2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	5%	2%		1%	3%	8%	3%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	0%	4%	3%	6%
Streptomycin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21%	31%	34%	21%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26%		33%	32%	29%	37%	27%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.32%	33%		26%	26%	31%	33%	41%	36%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48%	46%	36%		43%	37%	39%	56%	43%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.45%	30%	36%	37%	39%
Tetracycline	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.45%	46%	46%	45%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48%		47%	44%	48%	51%	41%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.51%	52%		46%	41%	48%	40%	49%	41%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.49%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.57%	53%	43%		49%	48%	45%	60%	57%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.52%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.59%	41%	40%	52%	46%
Trimethoprim-sulfamethoxazole	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%	6%	3%	4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%		1%	4%	3%	6%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	4%		3%	4%	4%	7%	11%	10%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12%	11%	10%		6%	12%	15%	16%	18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16%	16%	15%	20%	12%

Figure 13. Temporal variations in resistance of Campylobacter isolates from chicken

**Figure 13. Temporal variations in resistance of *Campylobacter* isolates from chicken**
Antimicrobial
Province	British Columbia							Saskatchewan									Ontario											Québec											Maritimes
Year	'07	'08	'09	'10	'11	'12		'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'09	'10	'11
Number of isolates	28	50	77	70	71	73		52	51	49	40	48	36	25	40		78	140	120	105	117	120	101	64	71	88		94	158	103	100	59	54	52	63	57	79		47	68	53
For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given province/region and antimicrobial. Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013. Although routine retail surveillance began in the Maritime region in 2008, no results are displayed for that year due to concerns regarding harmonization of laboratory methods. The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island. Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013. The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.
Azithromycin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%			Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	2%	2%	0%	0%	3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	8%	5%	4%	2%	8%	5%	9%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%		Significant differences (P ≤ 0.05) for a given antimicrobial.22%	16%	13%	9%	10%	11%	8%		3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	Significant differences (P ≤ 0.05) for a given antimicrobial.8%	6%	0%	0%
Ciprofloxacin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	8%	29%	17%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%		2%	6%	10%	15%	11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	Significant differences (P ≤ 0.05) for a given antimicrobial.4%	2%		3%	3%	1%	4%	1%	5%	Significant differences (P ≤ 0.05) for a given antimicrobial.6%	Significant differences (P ≤ 0.05) for a given antimicrobial.16%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	3%	2%		2%	14%	0%	0%	2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	4%	4%	9%
Gentamicin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	0%		0%	0%	0%	1%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	0%	0%		0%	0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%
Telithromycin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		2%	2%	0%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%		0%	4%	1%	4%	4%	6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%		1%	5%	2%	6%	5%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	6%	0%	0%
Tetracycline	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39%	32%	53%	43%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.54%		35%	39%	45%	60%	61%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.56%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.58%	47%		61%	55%	57%	49%	39%	53%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.46%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.70%	79%	70%		66%	54%	56%	62%	51%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.47%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.63%	53%	43%	55%

Figure 14. Temporal variations in resistance of Escherichia coli isolates from pork

**Figure 14. Temporal variations in resistance of *Escherichia coli* isolates from pork**
Antimicrobial
Province	British Columbia							Saskatchewan									Ontario											Québec											Maritimes
Year	'07	'08	'09	'10	'11	'12		'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'03	'04	'05	'06	'07	'08	'09	'10	'11	'12		'08	'09	'10	'11
Number of isolates	23	44	38	31	49	37		48	49	38	42	29	17	10	26		91	199	179	182	172	155	136	84	155	86		61	107	78	58	64	60	41	47	122	44		17	81	71	95
For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013. The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.
Ampicillin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13%	23%	8%	23%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%			Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	6%	5%	12%	10%	18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20%	23%	21%	21%	23%	17%	18%	11%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%		Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20%	19%	12%	19%	20%	18%	20%		21%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18%		18%	12%	23%	26%
Ceftiofur	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	7%	0%	13%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	3%	7%	3%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	1%		1%	1%	1%	1%	0%	2%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	2%	3%		0%	0%	3%	0%	4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	3%	2%
Gentamicin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	5%	5%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	0%	2%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	3%		1%	1%	1%	3%	1%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	3%	1%		3%	2%	2%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	0%	2%	3%	2%
Nalidixic acid	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%	3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%		0%	0%	2%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%		0%	0%	1%	0%	0%	1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	0%	0%		0%	0%	5%	0%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%	0%	1%	1%	0%
Streptomycin	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13%	23%	18%	6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.14%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%		10%	5%	14%	17%	18%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16%	26%		20%	20%	21%	14%	24%	17%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%	21%	17%		19%	23%	13%	17%	23%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.23%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36%	12%	25%	15%	36%
Tetracycline	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35%	45%	34%	32%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27%		31%	24%	29%	34%	35%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.60%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.55%	55%		49%	48%	46%	38%	35%	33%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.58%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48%	36%	33%		36%	45%	35%	27%	34%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.58%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48%	41%	48%	59%	58%
Trimethoprim-sulfamethoxazole	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%	7%	8%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%		2%	5%	0%	3%	0%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%	7%		7%	4%	5%	7%	7%	5%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10%	7%	6%		7%	3%	10%	10%	11%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15%	Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%	12%	7%	13%	14%

Minimum Inhibitory Concentrations

More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.

**Table 17. Distribution of minimum inhibitory concentrations among *Escherichia coli* from beef**
	Antimicrobial	Province / region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Province / region	n	MIC 50	MIC 90	% R	≤ 0,015	0,03	0,06	0,12	0,25	0,5	1	2	4	8	16	32	64	128	256	>256
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Amoxicillin-clavulanic acid	British Columbia	70	4	4	1.4							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7 ^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
		Saskatchewan	78	4	4	1.3							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 ^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
		Ontario	110	4	8	0.9							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.2 ^{Table 17 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 ^{Table 17 - Footnote2}
		Québec	104	4	4	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8 ^{Table 17 - Footnote1}
	Ceftiofur	British Columbia	70	0.25	0.50	1.4				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.3		^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
		Saskatchewan	78	0.25	0.50	1.3				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.2		^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
		Ontario	110	0.25	0.50	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 ^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
		Québec	104	0.25	0.50	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.5		^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
	Ceftriaxone	British Columbia	70	<=0.25	<=0.25	1.4					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.6		^{Table 17 - Footnote1}		^{Table 17 - Footnote2}		1.4
		Saskatchewan	78	<=0.25	<=0.25	1.3					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.7		^{Table 17 - Footnote1}		^{Table 17 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
		Ontario	110	<=0.25	<=0.25	0.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 ^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
		Québec	104	<=0.25	<=0.25	0.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0		^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
	Ciprofloxacin	British Columbia	70	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0		^{Table 17 - Footnote1}				^{Table 17 - Footnote2}
		Saskatchewan	78	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0		^{Table 17 - Footnote1}				^{Table 17 - Footnote2}
		Ontario	110	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.2		^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9		^{Table 17 - Footnote2}
		Québec	104	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9	^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	^{Table 17 - Footnote2}
II	Ampicillin	British Columbia	70	2	4	4.3							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
		Saskatchewan	78	2	4	2.6							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.5	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6
		Ontario	110	2	4	8.2							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.4	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.2
		Québec	104	2	4	2.9							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.0	^{Table 17 - Footnote1}	1.0	^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.9
	Azithromycin	British Columbia	70	4	4	0.0						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	^{Table 17 - Footnote2}
		Saskatchewan	78	4	4	0.0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1		^{Table 17 - Footnote2}
		Ontario	110	4	4	0.9							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 ^{Table 17 - Footnote2}
		Québec	104	4	4	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.7		^{Table 17 - Footnote2}
	Cefoxitin	British Columbia	70	4	4	1.4							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 ^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4
		Saskatchewan	78	4	4	1.3							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 ^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
		Ontario	110	4	8	0.9							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
		Québec	104	4	4	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	^{Table 17 - Footnote2}
	Gentamicin	British Columbia	70	1	1	0.0						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
		Saskatchewan	78	1	1	0.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
		Ontario	110	1	2	1.8						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.2	^{Table 17 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
		Québec	104	1	1	0.0						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
	Kanamycin	British Columbia	70	<=8	<=8	1.4										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.6	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
		Saskatchewan	78	<=8	<=8	0.0										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}
		Ontario	110	<=8	<=8	3.6										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.4	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.6
		Québec	104	<=8	<=8	1.9										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1	^{Table 17 - Footnote1}		^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9
	Nalidixic acid	British Columbia	70	2	2	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.6			^{Table 17 - Footnote2}
		Saskatchewan	78	2	4	0.0						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.3			^{Table 17 - Footnote2}
		Ontario	110	2	4	1.8							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8			^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.8
		Québec	104	2	4	2.9							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.6			^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.9
	Streptomycin	British Columbia	70	<=32	64	20.0												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.3 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7
		Saskatchewan	78	<=32	<=32	9.0												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.4 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6
		Ontario	110	<=32	>64	19.1												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.2 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.9
		Québec	104	<=32	<=32	5.8												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9
	Trimethoprim-sulfamethoxazole	British Columbia	70	<=0.12	<=0.12	1.4				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4				^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
		Saskatchewan	78	<=0.12	<=0.12	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6				^{Table 17 - Footnote2}
		Ontario	110	<=0.12	<=0.12	7.3				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9				^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.3
		Québec	104	<=0.12	<=0.12	1.9				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9			^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9
III	Chloramphenicol	British Columbia	70	8	8	2.9								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.7 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
		Saskatchewan	78	8	8	0.0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.3 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3	^{Table 17 - Footnote2}
		Ontario	110	8	8	2.7								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.4 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7
		Québec	104	8	8	1.0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0
	Sulfisoxazole	British Columbia	70	<=16	>256	21.4											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.4 ^{Table 17 - Footnote2}
		Saskatchewan	78	<=16	>256	10.3											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.5				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.3 ^{Table 17 - Footnote2}
		Ontario	110	<=16	>256	16.4										^{Table 17 - Footnote2}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16.4 ^{Table 17 - Footnote2}
		Québec	104	<=16	32	7.7											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.3				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.7 ^{Table 17 - Footnote2}
	Tetracycline	British Columbia	70	<=4	>32	34.3									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25.7
		Saskatchewan	78	<=4	>32	17.9									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.8 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3	^{Table 17 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.9
		Ontario	110	<=4	>32	30.0									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.4 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28.2
		Québec	104	<=4	>32	15.4									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.7 ^{Table 17 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0 ^{Table 17 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.5

**Table 18. Distribution of minimum inhibitory concentrations among *Salmonella* from chicken**
	Antimicrobial	Province / region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Province / region	n	MIC 50	MIC 90	% R	≤ 0,015	0,03	0,06	0,12	0,25	0,5	1	2	4	8	16	32	64	128	256	>256
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Amoxicillin-clavulanic acid	British Columbia	53	<=1	>32	39.6							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9		^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.34.0
		Saskatchewan	46	<=1	>32	13.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6			^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.0
		Ontario	102	<=1	>32	22.5							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.6		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 ^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.6
		Québec	106	<=1	>32	28.3							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 ^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25.5
	Ceftiofur	British Columbia	53	1	>8	39.6						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 ^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.37.7
		Saskatchewan	46	1	>8	13.0						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.2	^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.9
		Ontario	102	1	>8	22.5						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 ^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.6
		Québec	106	1	>8	28.3						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.0	^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28.3
	Ceftriaxone	British Columbia	53	<=0.25	32	39.6					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.4		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8
		Saskatchewan	46	<=0.25	8	13.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.0		^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2
		Ontario	102	<=0.25	16	22.5					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.5		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.8
		Québec	106	<=0.25	16	28.3					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.7		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8
	Ciprofloxacin	British Columbia	53	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.1	^{Table 18 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8
		Saskatchewan	46	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.1	^{Table 18 - Footnote1}
		Ontario	102	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.8	^{Table 18 - Footnote1}
		Québec	106	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.2	^{Table 18 - Footnote1}
II	Ampicillin	British Columbia	53	<=1	>32	39.6							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.39.6
		Saskatchewan	46	<=1	>32	17.4							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6			^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.4
		Ontario	102	<=1	>32	31.4							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31.4
		Québec	106	<=1	>32	29.2							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.29.2
	Azithromycin	British Columbia	53	4	4	0.0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5
		Saskatchewan	46	4	4	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.5
		Ontario	102	4	8	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.5
		Québec	106	4	8	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.2
	Cefoxitin	British Columbia	53	2	>32	35.8							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7	^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.3
		Saskatchewan	46	2	32	10.9							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2 ^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
		Ontario	102	2	32	20.6							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.9	^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.9
		Québec	106	2	32	27.4							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5	^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7
	Gentamicin	British Columbia	53	0.50	1	0.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9		^{Table 18 - Footnote1}
		Saskatchewan	46	0.50	1	0.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2	^{Table 18 - Footnote1}
		Ontario	102	0.50	1	0.0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.7		^{Table 18 - Footnote1}
		Québec	106	0.50	1	2.8					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.0		^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8
	Kanamycin	British Columbia	53	<=8	<=8	0.0										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	^{Table 18 - Footnote1}
		Saskatchewan	46	<=8	<=8	0.0										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	^{Table 18 - Footnote1}
		Ontario	102	<=8	<=8	0.0										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	^{Table 18 - Footnote1}
		Québec	106	<=8	<=8	0.9										Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.1	^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
	Nalidixic acid	British Columbia	53	4	4	3.8								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8
		Saskatchewan	46	4	4	0.0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3
		Ontario	102	4	4	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9
		Québec	106	4	4	0.0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.9
	Streptomycin	British Columbia	53	<=32	>64	26.4												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9
		Saskatchewan	46	<=32	>64	17.4												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.0
		Ontario	102	<=32	>64	23.5												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.7
		Québec	106	<=32	>64	30.2												Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.0
	Trimethoprim-sulfamethoxazole	British Columbia	53	<=0.12	<=0.12	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0
		Saskatchewan	46	<=0.12	<=0.12	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.8		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2
		Ontario	102	<=0.12	<=0.12	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0
		Québec	106	<=0.12	<=0.12	0.0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9
III	Chloramphenicol	British Columbia	53	4	8	0.0									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.2 ^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9
		Saskatchewan	46	8	8	4.3								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.2 ^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
		Ontario	102	8	8	1.0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.7 ^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0
		Québec	106	8	8	0.9								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.5 ^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
	Sulfisoxazole	British Columbia	53	32	64	0.0											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.3
		Saskatchewan	46	32	64	4.3											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
		Ontario	102	32	64	2.9											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.9
		Québec	106	32	64	5.7											Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7
	Tetracycline	British Columbia	53	<=4	>32	30.2									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.9 ^{Table 18 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.30.2
		Saskatchewan	46	<=4	>32	19.6									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.4 ^{Table 18 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.2
		Ontario	102	<=4	>32	29.4									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6 ^{Table 18 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28.4
		Québec	106	<=4	>32	31.1									Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.9 ^{Table 18 - Footnote1}				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31.1

**Table 19. Distribution of minimum inhibitory concentrations among *Escherichia coli* from chicken**
	Antimicrobial	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Province/region	n	MIC 50	MIC 90	% R	≤ 0,015	0,03	0,06	0,12	0,25	0,5	1	2	4	8	16	32	64	128	256	>256
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Amoxicillin-clavulanic acid	British Columbia	74	8	>32	43.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.29.7	13.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	64	4	32	23.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	14.1	9.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	107	4	32	19.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.2 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.1	7.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	128	4	32	26.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.2 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9	18.8	7.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftiofur	British Columbia	74	0.50	>8	39.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.6	17.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	64	0.50	8	21.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 ^{Table 19 - Footnote1}		14.1	7.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	107	0.50	8	18.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.3	9.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	128	0.50	8	25.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	17.2	7.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftriaxone	British Columbia	74	<=0.25	16	40.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1		21.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.8		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	64	<=0.25	16	21.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6		6.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.4	6.3		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	107	<=0.25	16	18.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}			Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6	10.3	2.8			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	128	<=0.25	16	26.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}			9.4	14.1	3.1		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ciprofloxacin	British Columbia	74	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.				Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	64	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7					Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	107	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9						Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	128	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.				Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
II	Ampicillin	British Columbia	37	2	>32	18.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}			59.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	2	>32	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.1	^{Table 19 - Footnote1}			28.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	>32	29.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 ^{Table 19 - Footnote1}		0.9	43.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	2	>32	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.		43.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Azithromycin	British Columbia	37	4	8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	0.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Cefoxitin	British Columbia	37	4	>32	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	9.5	31.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	4	4	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	3.1	20.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	4	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.5 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6	14.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	4	8	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.5	14.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	British Columbia	37	1	1	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1	^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4	5.4	6.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	1	1	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	1.6	7.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	1	1	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	3.7	8.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	1	2	4.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.1	21.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Kanamycin	British Columbia	37	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1 ^{Table 19 - Footnote1}			2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 ^{Table 19 - Footnote1}			10.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=8	>64	10.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 ^{Table 19 - Footnote1}			14.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=8	>64	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 ^{Table 19 - Footnote1}		0.8	18.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Nalidixic acid	British Columbia	37	2	4	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		1.4	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	2	2	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7			3.1		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	2	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9		1.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	2	4	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	0.8	0.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Streptomycin	British Columbia	37	<=32	>64	13.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.8	25.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=32	>64	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.7	31.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=32	>64	30.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6	22.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=32	>64	36.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.2	28.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Trimethoprim-sulfamethoxazole	British Columbia	37	<=0.12	<=0.12	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4				9.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=0.12	0.25	7.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1				1.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=0.12	0.25	4.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			7.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=0.12	0.25	9.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8			15.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
III	Chloramphenicol	British Columbia	37	8	8	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.3 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4		10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	8	8	7.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.5 ^{Table 19 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	8	8	8.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.3 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.	0.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	8	8	6.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.4 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.	3.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Sulfisoxazole	British Columbia	37	<=16	>256	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		35.1
		Saskatchewan	26	<=16	>256	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6			20.3
		Ontario	86	<=16	>256	23.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			27.1
		Québec	44	<=16	>256	38.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		49.2
	Tetracycline	British Columbia	37	<=4	>32	24.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.1 ^{Table 19 - Footnote1}				2.7	39.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=4	>32	34.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.1 ^{Table 19 - Footnote1}		1.6		34.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	>32	>32	58.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.4 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		0.9	47.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=4	>32	47.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.8 ^{Table 19 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8	0.8	57.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
IV							Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity

**Table 20. Distribution of minimum inhibitory concentrations among *Campylobacter* from chicken**
	Antimicrobial	Species	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Species	Province/region	n	MIC 50	MIC 90	% R	≤ 0,016	0,032	0,064	0,125	0,25	0,5	1	2	4	8	16	32	64	>64
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Ciprofloxacin	Campylobacter coli	British Columbia	7	0,125	16	42,9			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28,6			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter coli	Saskatchewan	3	0,125	0,125	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter coli	Ontario	10	0,064	16	10,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10,0			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter coli	Québec	3	0,25	16	33,3				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	British Columbia	66	0,125	0,125	4,5			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,5		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,5			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	Saskatchewan	36	0,125	0,125	5,6			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,6				Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	Ontario	75	0,125	8	13,3			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,3		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,3			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	Québec	76	0,125	0,25	1,3			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22,4		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3				Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter spp.	British Columbia	0	0	0	0,0							^{Table 20 - Footnote1}		^{Table 20 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter spp.	Saskatchewan	1	0,125	0,125	0,0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter spp.	Ontario	3	4	4	100,0							^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.100,0 ^{Table 20 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter spp.	Québec	0	0	0	0,0							^{Table 20 - Footnote1}		^{Table 20 - Footnote2}					Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	British Columbia	7	0,25	2	0,0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	Saskatchewan	3	2	2	0,0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	Ontario	10	2	16	10,0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 ^{Table 20 - Footnote1}		10,0 ^{Table 20 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	Québec	3	2	4	0,0								Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 ^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	British Columbia	66	0,5	1	0,0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,2		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	Saskatchewan	36	0,5	1	0,0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,6	^{Table 20 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8	^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	Ontario	75	0,5	2	2,7					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7 ^{Table 20 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	2,7 ^{Table 20 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	Québec	76	1	2	0,0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3 ^{Table 20 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,9	^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter spp.	British Columbia	0	0	0	0,0									^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter spp.	Saskatchewan	1	0,25	0,25	0,0					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter spp.	Ontario	3	1	1	0,0							Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter spp.	Québec	0	0	0	0,0									^{Table 20 - Footnote1}		^{Table 20 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
II	Azithromycin	Campylobacter coli	British Columbia	7	0,032	0,125	0,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter coli	Saskatchewan	3	0,125	0,125	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter coli	Ontario	10	0,064	> 64	20,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				20,0
	Azithromycin	Campylobacter coli	Québec	3	0,125	0,125	0,0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter jejuni	British Columbia	66	0,064	0,064	0,0		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter jejuni	Saskatchewan	36	0,064	0,064	2,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,6				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				2,8
	Azithromycin	Campylobacter jejuni	Ontario	75	0,064	0,064	5,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				5,3
	Azithromycin	Campylobacter jejuni	Québec	76	0,064	0,125	7,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,9				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				7,9
	Azithromycin	Campylobacter spp.	British Columbia	0	0	0	0,0								^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter spp.	Saskatchewan	1	0,032	0,032	0,0		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0						^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter spp.	Ontario	3	0,125	0,125	0,0				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter spp.	Québec	0	0	0	0,0								^{Table 20 - Footnote1}		^{Table 20 - Footnote2}				Discontinuation or no surveillance activity
	Clindamycin	Campylobacter coli	Saskatchewan	7	0,25	1	0,0	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter coli	Ontario	3	0,25	0,5	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter coli	Québec	10	0,25	16	30,0	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0		^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.20,0 ^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity ^{Table 20 - Footnote2}	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	British Columbia	3	1	8	33,3	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3 ^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Saskatchewan	66	0,125	0,25	0,0	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Ontario	36	0,125	0,25	0,0	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8		^{Table 20 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8	^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Québec	75	0,125	0,25	1,3	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7		^{Table 20 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3 ^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Maritimes	76	0,125	0,5	1,3	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,6		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 ^{Table 20 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3 ^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter spp.	British Columbia	0	0	0	0,0	Discontinuation or no surveillance activity							^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter spp.	Saskatchewan	1	0,25	0,25	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter spp.	Ontario	3	0,125	0,25	0,0	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter spp.	Québec	0	0	0	0,0	Discontinuation or no surveillance activity							^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Erythromycin	Campylobacter coli	British Columbia	7	0,25	2	0,0	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter coli	Saskatchewan	3	1	2	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter coli	Ontario	10	1	> 64	20,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		20,0
	Erythromycin	Campylobacter coli	Québec	3	2	2	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter jejuni	British Columbia	66	0,25	0,5	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19,7				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter jejuni	Saskatchewan	36	0,25	0,5	2,8	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,8	Discontinuation or no surveillance activity
	Erythromycin	Campylobacter jejuni	Ontario	75	0,25	0,5	5,3	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3	4,0
	Erythromycin	Campylobacter jejuni	Québec	76	0,5	2	7,9	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6		^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		7,9
	Erythromycin	Campylobacter spp.	British Columbia	0	0	0	0,0	Discontinuation or no surveillance activity									^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter spp.	Saskatchewan	1	0,125	0,125	0,0	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0						^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter spp.	Ontario	3	1	1	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter spp.	Québec	0	0	0	0,0	Discontinuation or no surveillance activity									^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
II	Gentamicin	Campylobacter coli	British Columbia	7	0,5	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	Saskatchewan	3	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	Ontario	10	0,5	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	Québec	3	1	2	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 ^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	British Columbia	66	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,0	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	Saskatchewan	36	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72,2	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	Ontario	75	0,5	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49,3	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	Québec	76	0,5	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43,4	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter spp.	British Columbia	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter spp.	Saskatchewan	1	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter spp.	Ontario	3	1	2	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 ^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter spp.	Québec	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					^{Table 20 - Footnote1}		^{Table 20 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter coli	British Columbia	7	16	> 64	42,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 ^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3 ^{Table 20 - Footnote2}	28,6
	Nalidixic acid	Campylobacter coli	Saskatchewan	3	8	16	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 ^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter coli	Ontario	10	8	> 64	10,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0 ^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	10,0
	Nalidixic acid	Campylobacter coli	Québec	3	8	> 64	33,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	33,3
	Nalidixic acid	Campylobacter jejuni	British Columbia	66	≤ 4	8	4,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31,8	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	4,5
	Nalidixic acid	Campylobacter jejuni	Saskatchewan	36	≤ 4	8	5,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	5,6
	Nalidixic acid	Campylobacter jejuni	Ontario	75	≤ 4	> 64	13,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24,0	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	13,3
	Nalidixic acid	Campylobacter jejuni	Québec	76	≤ 4	8	1,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	1,3
	Nalidixic acid	Campylobacter spp.	British Columbia	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter spp.	Saskatchewan	1	8	8	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter spp.	Ontario	3	> 64	> 64	100,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3 ^{Table 20 - Footnote2}	66,7
	Nalidixic acid	Campylobacter spp.	Québec	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Discontinuation or no surveillance activity
III	Florfenicol	Campylobacter coli	British Columbia	7	1	2	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9		^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter coli	Saskatchewan	3	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter coli	Ontario	10	1	2	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0		^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter coli	Québec	3	1	2	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3		^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	British Columbia	66	1	1	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90,9			^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	Saskatchewan	36	1	1	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8		^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	Ontario	75	1	1	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7		^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	Québec	76	1	2	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,5		^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter spp.	British Columbia	0	0	0	0,0	Discontinuation or no surveillance activity									^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter spp.	Saskatchewan	1	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter spp.	Ontario	3	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter spp.	Québec	0	0	0	0,0	Discontinuation or no surveillance activity									^{Table 20 - Footnote1}				Discontinuation or no surveillance activity
	Tetracycline	Campylobacter coli	British Columbia	7	1	64	28,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9			^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3 ^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3
	Tetracycline	Campylobacter coli	Saskatchewan	3	0,5	> 64	33,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		33,3
	Tetracycline	Campylobacter coli	Ontario	10	0,5	> 64	40,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10,0	30,0
	Tetracycline	Campylobacter coli	Québec	3	8	> 64	33,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 ^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		33,3
	Tetracycline	Campylobacter jejuni	British Columbia	66	0,25	64	25,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5			^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,5 ^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16,7	7,6
	Tetracycline	Campylobacter jejuni	Saskatchewan	36	32	> 64	52,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22,2					^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,6 ^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.22,2	25,0
	Tetracycline	Campylobacter jejuni	Ontario	75	32	> 64	50,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7			^{Table 20 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6,7 ^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16,0	28,0
	Tetracycline	Campylobacter jejuni	Québec	76	64	> 64	64,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,9		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	^{Table 20 - Footnote1}		^{Table 20 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25,0	39,5
	Tetracycline	Campylobacter spp.	British Columbia	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity								^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Tetracycline	Campylobacter spp.	Saskatchewan	1	0,5	0,5	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0				^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Tetracycline	Campylobacter spp.	Ontario	3	0,25	0,25	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7					^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
	Tetracycline	Campylobacter spp.	Québec	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity								^{Table 20 - Footnote1}		^{Table 20 - Footnote2}		Discontinuation or no surveillance activity
IV								Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity

**Table 21. Distribution of minimum inhibitory concentrations among *Escherichia coli* from pork**
	Antimicrobial	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Province/region	n	MIC 50	MIC 90	% R	≤ 0,015	0,03	0,06	0,12	0,25	0,5	1	2	4	8	16	32	64	128	256	>256
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Amoxicillin-clavulanic acid	British Columbia	37	4	32	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 ^{Table 21 - Footnote2}	8.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	4	8	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.4 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	8	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.2 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 ^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	4	8	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.3 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftiofur	British Columbia	37	0.50	8	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.4^{Table 21 - Footnote2}	5.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	0.50	0.50	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	0.25	0.50	1.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 ^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	0.50	0.50	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftriaxone	British Columbia	37	<=0.25	16	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.5		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=0.25	<=0.25	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.2		^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=0.25	<=0.25	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3					Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=0.25	<=0.25	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}					Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			^{Table 21 - Footnote1}		^{Table 21 - Footnote2}					Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ciprofloxacin	British Columbia	37	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4	^{Table 21 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 ^{Table 21 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 21 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 21 - Footnote2}				Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=0.015	<=0.015	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0			^{Table 21 - Footnote1}				^{Table 21 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
II	Ampicillin	British Columbia	37	2	>32	18.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	18.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	2	>32	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.2	^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	>32	29.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	29.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	2	>32	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3	^{Table 21 - Footnote2}	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Azithromycin	British Columbia	37	4	8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	^{Table 21 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8		^{Table 21 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity									^{Table 21 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Cefoxitin	British Columbia	37	4	>32	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8		^{Table 21 - Footnote2}	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	4	4	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	4	4	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 ^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	4	8	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity							^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	British Columbia	37	1	1	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4	^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	1	1	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	1	1	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	1	2	4.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6	^{Table 21 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 ^{Table 21 - Footnote2}	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Kanamycin	British Columbia	37	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=8	>64	10.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	10.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=8	>64	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Nalidixic acid	British Columbia	37	2	4	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 21 - Footnote2}	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	2	2	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7			^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	2	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	2	4	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 21 - Footnote2}	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity							^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Streptomycin	British Columbia	37	<=32	>64	13.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 ^{Table 21 - Footnote2}	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=32	>64	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.7 ^{Table 21 - Footnote2}	11.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=32	>64	30.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.1 ^{Table 21 - Footnote2}	15.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=32	>64	36.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.6 ^{Table 21 - Footnote2}	22.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity						^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Trimethoprim-sulfamethoxazole	British Columbia	37	<=0.12	<=0.12	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			^{Table 21 - Footnote2}	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=0.12	0.25	7.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			^{Table 21 - Footnote2}	7.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	<=0.12	0.25	4.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2		^{Table 21 - Footnote2}	4.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=0.12	0.25	9.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 21 - Footnote2}	9.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity						^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
III	Chloramphenicol	British Columbia	37	8	8	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.1 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	2.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	8	8	7.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8 ^{Table 21 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8 ^{Table 21 - Footnote2}	3.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	8	8	8.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.7 ^{Table 21 - Footnote2}	3.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	8	8	6.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 ^{Table 21 - Footnote2}	4.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			^{Table 21 - Footnote1}		^{Table 21 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Sulfisoxazole	British Columbia	37	<=16	>256	10.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		10.8 ^{Table 21 - Footnote2}
		Saskatchewan	26	<=16	>256	19.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			19.2 ^{Table 21 - Footnote2}
		Ontario	86	<=16	>256	23.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			23.3 ^{Table 21 - Footnote2}
		Québec	44	<=16	>256	38.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		38.6 ^{Table 21 - Footnote2}
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity						Discontinuation or no surveillance activity
	Tetracycline	British Columbia	37	<=4	>32	24.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.7 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		24.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	26	<=4	>32	34.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.4 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		34.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	86	>32	>32	58.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.7 ^{Table 21 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2	^{Table 21 - Footnote2}		58.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	44	<=4	>32	47.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.3 ^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		47.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Maritimes	0	0	0	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	^{Table 21 - Footnote1}		^{Table 21 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
IV							Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity

**Table 22. Distribution of minimum inhibitory concentrations in *Salmonella* from turkey**
	Antimicrobial	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Province/region	n	MIC 50	MIC 90	% R	≤ 0,015	0,03	0,06	0,12	0,25	0,5	1	2	4	8	16	32	64	128	256	>256
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Amoxicillin-clavulanic acid	British Columbia	27	<=1	>32	29.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.7 ^{Table 22 - Footnote2}	25.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	<=1	16	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6	^{Table 22 - Footnote2}	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=1	>32	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint. ^{Table 22 - Footnote2}	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=1	>32	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	^{Table 22 - Footnote2}	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftiofur	British Columbia	27	1	>8	33.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 ^{Table 22 - Footnote2}	25.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	1	1	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8	^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	1	>8	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	1	>8	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.8	^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftriaxone	British Columbia	27	<=0.25	16	37.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.0		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 ^{Table 22 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.5			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	<=0.25	<=0.25	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.4		^{Table 22 - Footnote1}		^{Table 22 - Footnote2}				Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=0.25	32	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=0.25	32	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ciprofloxacin	British Columbia	27	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	^{Table 22 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7	^{Table 22 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 22 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 22 - Footnote2}				Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=0.015	0.03	0.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
II	Ampicillin	British Columbia	27	<=1	>32	37.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	37.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	<=1	>32	11.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	11.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=1	>32	25.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	25.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=1	>32	39.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	39.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Azithromycin	British Columbia	27	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7		^{Table 22 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	4	8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2		^{Table 22 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	4	8	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	2.3 ^{Table 22 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	4	8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Cefoxitin	British Columbia	27	2	32	22.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.22.2 ^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	4	4	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	2	>32	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.5 ^{Table 22 - Footnote2}	15.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	4	>32	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.9 ^{Table 22 - Footnote2}	23.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	British Columbia	27	0.50	1	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4	^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	0.50	>16	16.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}	16.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	0.50	1	6.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}	6.8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	0.50	1	2.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	2.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Kanamycin	British Columbia	27	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=8	<=8	4.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	4.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=8	<=8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Nalidixic acid	British Columbia	27	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4		^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8			^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5		^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	4	4	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Streptomycin	British Columbia	27	<=32	>64	48.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 ^{Table 22 - Footnote2}	40.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	>64	>64	50.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0	^{Table 22 - Footnote2}	50.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=32	>64	20.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.8^{Table 22 - Footnote2}	13.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=32	>64	29.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.8 ^{Table 22 - Footnote2}	21.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Trimethoprim-sulfamethoxazole	British Columbia	27	<=0.12	<=0.12	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	<=0.12	0.25	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6			^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=0.12	<=0.12	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3			^{Table 22 - Footnote2}	2.3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=0.12	0.25	3.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		^{Table 22 - Footnote2}	3.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
III	Chloramphenicol	British Columbia	27	8	8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.3 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	8	8	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.7 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	5.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	8	>32	11.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.5 ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 22 - Footnote2}	11.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	8	8	0.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.4 ^{Table 22 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0	^{Table 22 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Sulfisoxazole	British Columbia	27	32	128	7.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7		7.4 ^{Table 22 - Footnote2}
		Saskatchewan	18	>256	>256	50.0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7			50.0 ^{Table 22 - Footnote2}
		Ontario	44	32	>256	11.4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5			11.4 ^{Table 22 - Footnote2}
		Québec	51	32	>256	15.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		15.7 ^{Table 22 - Footnote2}
	Tetracycline	British Columbia	27	>32	>32	51.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.1 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}		51.9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	18	>32	>32	66.7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6	61.1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	44	<=4	>32	18.2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.8 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.5	13.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	51	<=4	>32	23.5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.5 ^{Table 22 - Footnote1}		^{Table 22 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.0	21.6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
IV			0	0	0	0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity

**Table 23. Distribution of minimum inhibitory concentrations in *Escherichia coli* from turkey**
	Antimicrobial	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Province/region	n	MIC 50	MIC 90	% R	≤ 0,015	0,03	0,06	0,12	0,25	0,5	1	2	4	8	16	32	64	128	256	>256
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Amoxicillin-clavulanic acid	British Columbia	101	4	32	15,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18,8 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,9 ^{Table 23 - Footnote2}	5,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	4	8	4,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,0 ^{Table 23 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,9 ^{Table 23 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	4	32	11,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,4 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,2 ^{Table 23 - Footnote2}	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	4	32	12,4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,1 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,8 ^{Table 23 - Footnote2}	3,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftiofur	British Columbia	101	0,50	8	12,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,9 ^{Table 23 - Footnote2}	4,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	0,25	0,50	3,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	^{Table 23 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,5 ^{Table 23 - Footnote2}	1,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	0,50	1	8,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,6 ^{Table 23 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	0,50	8	11,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8	^{Table 23 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,7 ^{Table 23 - Footnote2}	6,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ceftriaxone	British Columbia	101	≤ 0,25	8	13,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83,2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,0 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6,9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,0		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	≤ 0,25	≤ 0,25	3,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96,3		^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,5			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	≤ 0,25	0,50	9,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,3	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,3		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	≤ 0,25	8	11,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88,2		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,8		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ciprofloxacin	British Columbia	101	≤ 0,015	≤ 0,015	0,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0	^{Table 23 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0	^{Table 23 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	≤ 0,015	≤ 0,015	0,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	^{Table 23 - Footnote1}		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,5		^{Table 23 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	≤ 0,015	≤ 0,015	0,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0	^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3		^{Table 23 - Footnote2}			0,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	≤ 0,015	≤ 0,015	0,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6 ^{Table 23 - Footnote1}			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	^{Table 23 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
II	Ampicillin	British Columbia	101	2	> 32	30,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,8	^{Table 23 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,0 ^{Table 23 - Footnote2}	29,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	2	> 32	24,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,6	^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	24,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	2	> 32	30,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,8	^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	30,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	4	> 32	37,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	37,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Azithromycin	British Columbia	101	4	4	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9		^{Table 23 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	4	4	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,4		^{Table 23 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	4	8	1,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7	1,3 ^{Table 23 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	4	4	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6	^{Table 23 - Footnote2}Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Cefoxitin	British Columbia	101	4	> 32	14,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,0 ^{Table 23 - Footnote2}	10,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	4	8	3,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,4 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,2 ^{Table 23 - Footnote2}	2,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	4	32	10,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,6 ^{Table 23 - Footnote2}	5,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	4	32	11,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,6 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,1 ^{Table 23 - Footnote2}	7,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	British Columbia	101	1	2	6,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9	^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,0 ^{Table 23 - Footnote2}	4,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	1	16	13,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,7 ^{Table 23 - Footnote2}	9,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	1	> 16	15,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,0 ^{Table 23 - Footnote2}	13,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	1	2	9,4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,2	^{Table 23 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,4 ^{Table 23 - Footnote2}	7,1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Kanamycin	British Columbia	101	≤ 8	16	9,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	9,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	≤ 8	> 64	12,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,2 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	12,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	≤ 8	> 64	10,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,9 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	10,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	≤ 8	≤ 8	8,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	8,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Nalidixic acid	British Columbia	101	2	4	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,9			^{Table 23 - Footnote2}	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	2	2	2,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,2			^{Table 23 - Footnote2}	2,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	2	4	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7		^{Table 23 - Footnote2}	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	2	4	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2	^{Table 23 - Footnote2}	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Streptomycin	British Columbia	101	≤ 32	> 64	45,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54,5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7,9 ^{Table 23 - Footnote2}	37,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	≤ 32	> 64	44,4	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,6	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18,5 ^{Table 23 - Footnote2}	25,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	≤ 32	> 64	34,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65,1	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7,2 ^{Table 23 - Footnote2}	27,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	≤ 32	> 64	36,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63,5	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,4 ^{Table 23 - Footnote2}	27,1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Trimethoprim-sulfamethoxazole	British Columbia	101	≤ 0,12	≤ 0,12	3,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0			^{Table 23 - Footnote2}	3,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	≤ 0,12	≤ 0,12	1,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9				^{Table 23 - Footnote2}	1,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	≤ 0,12	0,25	8,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7			^{Table 23 - Footnote2}	8,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	≤ 0,12	> 4	11,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6		^{Table 23 - Footnote2}	11,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
III	Chloramphenicol	British Columbia	101	8	8	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52,5 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	2,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	4	8	1,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,2	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46,9 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	1,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	8	8	5,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,1 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0,7 ^{Table 23 - Footnote2}	4,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	4	8	5,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39,4 ^{Table 23 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0,6 ^{Table 23 - Footnote2}	5,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Sulfisoxazole	British Columbia	101	≤ 16	> 256	25,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0			25,7 ^{Table 23 - Footnote2}
		Saskatchewan	81	≤ 16	> 256	24,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2			24,7 ^{Table 23 - Footnote2}
		Ontario	152	32	> 256	27,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,3			27,6 ^{Table 23 - Footnote2}
		Québec	170	32	> 256	28,8	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6		28,8 ^{Table 23 - Footnote2}
	Tetracycline	British Columbia	101	≤ 4	> 32	46,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,5 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,0	44,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Saskatchewan	81	> 32	> 32	51,9	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,1 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,2	50,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Ontario	152	> 32	> 32	59,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,8 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0,7	58,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		Québec	170	> 32	> 32	58,2	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,8 ^{Table 23 - Footnote1}		^{Table 23 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,9	55,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
IV							Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity

**Table 24. Distribution of minimum inhibitory concentrations in *Campylobacter* from turkey**
	Antimicrobial	Species	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
	Antimicrobial	Species	Province/region	n	MIC 50	MIC 90	% R	≤ 0,016	0,032	0,064	0,125	0,25	0,5	1	2	4	8	16	32	64	>64
1Antimicrobial susceptibility breakpoints 2Antimicrobial resistance breakpoints
I	Ciprofloxacin	Campylobacter coli	British Columbia	7	16	16	57,1			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.57,1			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter coli	Saskatchewan	0	0	0	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter coli	Ontario	8	0,25	0,25	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter coli	Québec	1	0,25	0,25	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	British Columbia	26	0,125	16	11,5			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11,5			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	Saskatchewan	6	0,064	16	16,7			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16,7			Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	Ontario	12	0,125	0,25	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}					Discontinuation or no surveillance activity
	Ciprofloxacin	Campylobacter jejuni	Québec	14	0,125	0,25	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}					Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	British Columbia	7	0,25	0,25	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	^{Table 24 - Footnote1}		^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	Saskatchewan	0	0	0	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	Ontario	8	2	16	12,5			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62,5	^{Table 24 - Footnote1}		12,5 ^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter coli	Québec	1	2	2	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	British Columbia	26	0,5	1	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38,5		^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	Saskatchewan	6	0,5	1	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7		^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	Ontario	12	0,5	1	8,3			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0		^{Table 24 - Footnote1}		8,3 ^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Telithromycin	Campylobacter jejuni	Québec	14	1	2	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
II	Azithromycin	Campylobacter coli	British Columbia	7	0,064	0,064	0,0		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1					^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter coli	Saskatchewan	0	0	0	0,0								^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter coli	Ontario	8	0,064	> 64	12,5		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0					^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				12,5
	Azithromycin	Campylobacter coli	Québec	1	0,064	0,064	0,0			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0					^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter jejuni	British Columbia	26	0,064	0,064	0,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,7				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter jejuni	Saskatchewan	6	0,064	0,064	0,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0					^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				Discontinuation or no surveillance activity
	Azithromycin	Campylobacter jejuni	Ontario	12	0,032	0,125	8,3		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,3				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				8,3
	Azithromycin	Campylobacter jejuni	Québec	14	0,064	0,064	0,0		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,1				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}				Discontinuation or no surveillance activity
	Clindamycin	Campylobacter coli	Saskatchewan	7	0,25	0,25	0,0	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85,7			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter coli	Ontario	0	0	0	0,0	Discontinuation or no surveillance activity							^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter coli	Québec	8	0,25	8	12,5	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5		^{Table 24 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12,5 ^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	British Columbia	1	0,25	0,25	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Saskatchewan	26	0,125	0,25	0,0	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38,5			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Ontario	6	0,125	0,125	0,0	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83,3				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Québec	12	0,125	0,125	0,0	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58,3				^{Table 24 - Footnote1}	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,3	^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Clindamycin	Campylobacter jejuni	Maritimes	14	0,125	0,25	0,0	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,4			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Erythromycin	Campylobacter coli	British Columbia	7	0,25	0,25	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0					^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter coli	Saskatchewan	0	0	0	0,0	Discontinuation or no surveillance activity									^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter coli	Ontario	8	1	> 64	12,5	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,5			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		12,5
	Erythromycin	Campylobacter coli	Québec	1	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter jejuni	British Columbia	26	0,25	1	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,4			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter jejuni	Saskatchewan	6	0,25	0,5	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity
	Erythromycin	Campylobacter jejuni	Ontario	12	0,25	0,5	8,3	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		8,3
	Erythromycin	Campylobacter jejuni	Québec	14	0,5	1	0,0	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	British Columbia	7	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	Saskatchewan	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	Ontario	8	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter coli	Québec	1	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	British Columbia	26	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,8	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	Saskatchewan	6	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	Ontario	12	1	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Gentamicin	Campylobacter jejuni	Québec	14	0,5	1	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter coli	British Columbia	7	> 64	> 64	57,1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9		^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	57,1
	Nalidixic acid	Campylobacter coli	Saskatchewan	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter coli	Ontario	8	8	8	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62,5	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter coli	Québec	1	8	8	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter jejuni	British Columbia	26	8	> 64	11,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,7 ^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	11,5
	Nalidixic acid	Campylobacter jejuni	Saskatchewan	6	8	> 64	16,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	16,7
	Nalidixic acid	Campylobacter jejuni	Ontario	12	≤ 4	8	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Discontinuation or no surveillance activity
	Nalidixic acid	Campylobacter jejuni	Québec	14	≤ 4	8	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3				Discontinuation or no surveillance activity
III	Florfenicol	Campylobacter coli	British Columbia	7	1	2	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71,4	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6		^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter coli	Saskatchewan	0	0	0	0,0	Discontinuation or no surveillance activity									^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter coli	Ontario	8	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter coli	Québec	1	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	British Columbia	26	1	2	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,8	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,8	^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	Saskatchewan	6	1	1	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7			^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	Ontario	12	1	1	0,0	Discontinuation or no surveillance activity						Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0			^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Florfenicol	Campylobacter jejuni	Québec	14	1	2	0,0	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,1	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78,6	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3		^{Table 24 - Footnote1}				Discontinuation or no surveillance activity
	Tetracycline	Campylobacter coli	British Columbia	7	> 64	> 64	85,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity					Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3			^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3	71,4
	Tetracycline	Campylobacter coli	Saskatchewan	0	0	0	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity								^{Table 24 - Footnote1}		^{Table 24 - Footnote2}
	Tetracycline	Campylobacter coli	Ontario	8	> 64	> 64	62,5	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}		62,5
	Tetracycline	Campylobacter coli	Québec	1	0,5	0,5	0,0	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity				Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0				^{Table 24 - Footnote1}		^{Table 24 - Footnote2}
	Tetracycline	Campylobacter jejuni	British Columbia	26	0,25	64	23,1	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity		Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,5	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,8		^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19,2	3,8
	Tetracycline	Campylobacter jejuni	Saskatchewan	6	32	64	66,7	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7				^{Table 24 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3 ^{Table 24 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3
	Tetracycline	Campylobacter jejuni	Ontario	12	64	> 64	83,3	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,3	Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,3				^{Table 24 - Footnote1}		Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,3 ^{Table 24 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.50,0	25,0
	Tetracycline	Campylobacter jejuni	Québec	14	64	> 64	78,6	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity			Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3				7,1	^{Table 24 - Footnote1}		^{Table 24 - Footnote2}	Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35,7	42,9
IV								Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity

Recovery Results

**Table 25. Retail surveillance recovery rates, 2003-2012**
CIPARS Component/Animal species	Province	Year	Percentage (%) of isolates recovered and number of isolates recovered / number of samples submitted
CIPARS Component/Animal species	Province	Year	Escherichia coli		Salmonella		Campylobacter		Enterococcus
aIn 2011, due to an unforeseeable pause in retail sampling in Saskatchewan of approximately 3 months, the expected number of samples was not met and thus, results for this province for this year should be interpreted with caution. bEnhancement to the Salmonella recovery method yielded higher recovery rates from retail chicken in 2007 than in prior years. cFor the Maritimes, recovery results are not presented for Campylobacter in 2007 and 2008 as well as for Enterococcus in 2007, 2008, and 2009 due to concerns regarding harmonization of laboratory methods. dDue to an unforeseeable pause in retail sampling in the Maritimes from April through December in 2012, the expected number of samples was not achieved and thus, results for this region in 2012 are not representative and potentially lack the precision necessary to be included as regular surveillance data. For this reason, these data are not presented anywhere else in this chapter.
Beef	British Columbia	2005	93%	27/29		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	79%	49/62	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	77%	88/115	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	71%	79/112	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	51%	64/125	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	53%	57/107	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	60%	76/126	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Saskatchewan	2005	79%	120/151		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2006	76%	123/161	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	78%	118/151	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	76%	134/177	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	83%	135/163	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	80%	107/134	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011^{Tableau 25 - Note de bas de page a}	75%	54/72	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	75%	80/107	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ontario	2003	66%	101/154	2%	2/84	3%	2/76	91%	96/76
		2004	80%	190/237	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2005	81%	184/227	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2006	81%	189/235	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	71%	184/227	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	78%	185/236	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	79%	195/248	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	69%	123/177	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	73%	161/222	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	63%	110/176	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Québec	2003	57%	84/147	0%	0/33	0%	0/33	80%	28/35
		2004	56%	137/245	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2005	56%	126/225	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2006	50%	109/215	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	68%	147/216	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	59%	126/214	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	54%	108/201	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	46%	102/223	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	45%	91/204	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	51%	107/219	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Maritimes	2004	67%	16/24	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	52%	16/31	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	70%	39/56	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	69%	137/200	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	69%	126/183	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	58%	110/191	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012^{Tableau 25 - Note de bas de page d}	50%	24/48	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
Chicken	British Columbia	2005	95%	19/20	13%	5/39	69%	27/39	100%	20/20
		2007	98%	42/43	22%b	18/81	35%	28/80	100%	34/34
		2008	90%	70/78	32%	47/145	34%	50/145	100%	78/78
		2009	95%	70/74	40%	59/146	53%	78/146	97%	72/74
		2010	89%	75/84	34%	56/166	42%	70/166	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	96%	70/73	45%	64/143	50%	71/143	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	99%	82/83	32%	53/166	44%	73/166	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Saskatchewan	2005	98%	81/83	14%	21/153	37%	53/145	98%	83/85
		2006	98%	85/86	16%	25/153	33%	51/155	98%	85/87
		2007	97%	75/77	31%b	43/141	35%	49/141	100%	77/77
		2008	99%	91/92	40%	64/161	25%	41/161	100%	92/92
		2009	98%	90/92	47%	71/150	32%	48/150	100%	92/92
		2010	90%	71/79	32%	42/132	28%	37/132	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011^{Tableau 25 - Note de bas de page a}	97%	38/39	40%	29/73	34%	25/73	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	94%	67/71	33%	46/140	29%	40/140	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ontario	2003	95%	137/144	16%	27/167	47%	78/166	99%	143/144
		2004	95%	150/158	17%	54/315	45%	143/315	100%	158/158
		2005	95%	145/153	9%	26/303	40%	120/303	99%	150/152
		2006	97%	152/156	12%	36/311	34%	104/311	98%	154/156
		2007	98%	157/161	54%b	172/320	37%	117/320	100%	161/161
		2008	96%	150/156	45%	139/311	39%	121/311	99%	154/156
		2009	95%	155/164	43%	142/328	31%	101/328	100%	164/164
		2010	86%	100/116	39%	90/232	28%	64/232	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	93%	137/147	40%	119/294	24%	71/293	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	92%	107/116	44%	102/232	39%	87/226	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Québec	2003	89%	112/126	16%	29/171	55%	94/170	100%	125/125
		2004	96%	157/161	17%	53/320	50%	161/322	100%	161/161
		2005	95%	142/149	9%	26/300	34%	103/299	100%	150/150
		2006	94%	135/144	12%	33/288	35%	100/288	100%	144/144
		2007	90%	129/144	40%b	113/287	21%	59/287	99%	143/144
		2008	91%	131/144	42%	120/287	19%	54/287	100%	144/144
		2009	94%	126/134	39%	105/267	20%	52/266	99%	132/134
		2010	93%	138/148	39%	116/296	21%	63/296	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	99%	134/136	37%	100/272	21%	57/272	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	95%	133/140	38%	106/280	28%	78/274	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Maritimes	2004	100%	13/13	4%	1/25	40%	10/25	Discontinuation or no surveillance activity100%	Discontinuation or no surveillance activity13/13
		2007	91%	29/32	22%b	7/32			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	68%	38/56	22%	12/56			Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	94%	187/199	49%	97/199	29%	57/199	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	93%	176/190	41%	77/190	37%	70/190	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	89%	171/192	28%	53/192	30%	57/192	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012^{Tableau 25 - Note de bas de page d}	96%	46/48	23%	11/48	21%	10/48	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
Pork	British Columbia	2005	31%	10/32		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	29%	23/79	1%	1/79	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	30%	44/148	2%	3/148	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	26%	38/145	1%	2/145	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	19%	31/166	1%	2/167	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	27%	49/180	2%	3/180	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	25%	41/167	0%	0/167	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Saskatchewan	2005	30%	48/162		Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2006	30%	49/165	2%	3/134	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	25%	38/154	2%	3/154	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	23%	41/176	1%	1/176	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	18%	29/164	0%	0/164	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	12%	17/142	1%	1/142	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011^{Tableau 25 - Note de bas de page a}	11%	10/90	1%	1/90	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	19%	26/140	1%	2/141	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ontario	2003	58%	90/154	1%	1/93	0%	0/76	87%	66/76
		2004	71%	198/279	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2005	59%	179/303	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2006	59%	182/311	< 1%	1/255	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	54%	172/320	2%	6/319	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	50%	155/312	2%	7/310	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	41%	136/328	2%	8/327	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	38%	84/224	0%	0/224	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	42%	155/371	2%	6/370	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	37%	86/231	2%	5/231	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Québec	2003	42%	61/147	3%	1/32	9%	3/32	82%	28/34
		2004	38%	109/290	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2005	26%	79/300	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2006	20%	57/287	0%	0/232	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	22%	64/287	1%	3/288	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	21%	60/287	2%	5/286	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	15%	41/268	1%	3/268	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	16%	47/296	1%	4/296	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	32%	122/387	4%	17/387	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012	16%	46/279	3%	8/279	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Maritimes	2004	58%	14/24	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2007	39%	13/31	3%	1/30	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2008	30%	17/56	2%	1/56	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2009	41%	82/200	3%	5/199	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2010	39%	74/190	4%	8/190	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2011	43%	95/223	3%	7/221	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
		2012^{Tableau 25 - Note de bas de page d}	25%	12/48	0%	0/48	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
Turkey	British Columbia	2011	97%	59/61	11%	8/71	24%	17/71	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	British Columbia	2012	97%	101/104	18%	27/153	22%	33/153
	Saskatchewan	2011^{Tableau 25 - Note de bas de page a}	100%	10/10	20%	2/10	10%	1/10	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Saskatchewan	2012	91%	81/89	14%	18/128	5%	6/128
	Ontario	2011	95%	162/171	14%	27/191	9%	18/191	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Ontario	2012	97%	152/156	20%	44/223	9%	20/223
	Québec	2011	91%	138/152	17%	27/163	10%	16/163	Discontinuation or no surveillance activity	Discontinuation or no surveillance activity
	Québec	2012	96%	170/178	21%	51/246	6%	15/246

Grey-shaded areas indicate either: a) isolates recovered from sampling activities outside the scope of CIPARS routine (or core) surveillance in the specified year (i.e. grey-shaded areas with data) or b) discontinuation or no surveillance activity (i.e. grey-shaded areas with no data).
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.

Page details

Date modified:: 2015-04-29

Language selection

Search